New research has identified a protein that could serve as both a biomarker and therapeutic target to weaken stem-like cancer ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

Aging and cancer are deeply intertwined: advancing age is the single largest risk factor for most malignancies, and many of the molecular processes that ...

Druggable phosphatases in cancer and immune cells, with examples of their corresponding drugs. Structures of allosteric inhibitors targeting PP2A, PRL3, DUSP1/6, and SHP2 in cancer cells (left).

Children with lesions on the top or back of the tongue often face significant challenges with eating and speaking. With ...

Scientists at The Wistar Institute and ChristianaCare’s Helen F. Graham Cancer Center & Research Institute have uncovered a ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

Scientists at The Wistar Institute and clinical researchers from ChristianaCare’s Helen F. Graham Cancer Center & Research ...

QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular ...

Beyond weight loss, GLP-1s may offer a "two-for-one" benefit by protecting heart health, which is the leading cause of ...

Lifestyle and chemical exposures-from diet to pesticides, herbicides-are increasingly linked to rising colon cancer rates in ...